Patented Medicine Prices Review Board
canada.ca
Imported from official source
Regulator in Canada; financial publications from its own official source.
Publications 25
-
Federal Minister of Health tables the 2024 Annual Report of the Patented Medicine Prices Review Board
Sales of patented medicines in Canada were $22.1 billion in 2024, a 10.9% increase over the year before.
Announcement -
Canadian public drug plan spending grew by $3.4 billion over 5 years, driven by use of higher-cost drugs
The latest edition of the PMPRB CompassRx report shows that prescription drug expenditure for public drug plans grew by 7.4% in 2022/23 to reach $14.1 billion, compared to $13.2 billion in 2021/22.
Announcement -
PMPRB report reviews potential impact of new medicines on the Canadian market
The Patented Medicine Prices Review Board published the 9th edition of its annual Meds Entry Watch report today.
Announcement -
Anie Perrault to lead PMPRB as Acting Chairperson
Chairperson of the PMPRB, Mr. Thomas Digby has stepped down from his role, effective March 6, 2025.
Announcement -
PMPRB report shows higher-cost medicines driving a 14.1% growth in private plan drug costs in 2023
Report explores the drivers of growth in prescription drug costs for private drug plans
Announcement -
Federal Minister of Health tables the 2023 Annual Report of the Patented Medicine Prices Review Board
86 new patented medicines were reported to the PMPRB in 2023
Announcement -
PMPRB report reviews new drugs and their potential impact on future drug spending in Canada
The latest edition of Meds Pipeline Monitor provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spen...
Announcement -
PMPRB report examines availability and pricing of new medicines
The Patented Medicine Prices Review Board published the 8th edition of its annual Meds Entry Watch report today.
Announcement -
Federal Minister of Health tables the 2022 Annual Report of the Patented Medicine Prices Review Board
The Honourable Mark Holland, Federal Minister of Health, today tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Comm...
Announcement -
PMPRB releases What We Learned Report from recent Policy Roundtable
The Patented Medicine Prices Review Board (PMPRB) today published its What We Learned Report, which summarizes the feedback received in the Policy Roundtable meetings it hosted in December. The rep...
Announcement -
PMPRB release analyzes key cost pressures driving changes in public plan prescription drug expenditures
PMPRB report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000.
Announcement -
PMPRB announces next steps in Guidelines consultation process
The Patented Medicine Prices Review Board (PMPRB) will launch the first phase of consultations on its new Guidelines by inviting stakeholders to participate in a Policy Roundtable.
Announcement -
PMPRB report reveals most new medicines come to market with high treatment costs
The Patented Medicine Prices Review Board (PMPRB) published today the 7th edition of its annual Meds Entry Watch report.
Announcement -
New report examines new drugs in the pipeline that may significantly impact future drug spending in Canada
Oncology continued to dominate the therapeutic mix of the drug pipeline in 2022.
Announcement -
PMPRB consults on new proposed Interim Guidance
Announcement -
Spending on antidiabetic drugs in Canada outpaced overall drug market
Canadian prices for top-selling antidiabetic drugs were higher than those in the PMPRB’s comparator countries from 2012 to 2021.
Announcement -
Patented Medicine Prices Review Board seeks applicants for vacant Board positions
The Government of Canada is seeking applicants for the Vice Chairperson position and two Board Member positions on the Patented Medicine Prices Review Board by way of open, transparent, and merit-b...
Announcement -
Douglas Clark stepping down as Executive Director of the PMPRB
Douglas Clark, Executive Director of the Patented Medicine Prices Review Board (PMPRB), has announced that he will be stepping down from that position after almost a decade at the PMPRB.
Announcement -
Increased use of higher-cost medicines continues to put pressure on Canadian public drug plans
A new Patented Medicine Prices Review Board (PMPRB) report finds that prescription drug expenditures by Canadian public drug plans increased by 4.2% in 2020-21, bringing annual spending to $12.3 bi...
Announcement -
Federal Minister of Health tables the 2021 Annual Report of the Patented Medicine Prices Review Board
The Honourable Jean-Yves Duclos, Federal Minister of Health, tabled the 2021 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the Senate and the House of Commons on Fri...
Announcement -
PMPRB Hearing Panel issues order in Procysbi case
In an order dated October 13, 2022, the Hearing Panel directed Horizon to pay $22,028,977.26 to the Receiver General of Canada within 30 days of the date of the Order. It is the largest amount ever...
Announcement -
Federal drug price watchdog consulting public on proposed changes to its pricing guidelines
The Patented Medicine Prices Review Board (PMPRB) released its new draft Guidelines today and launched a 60-day consultation period with stakeholders and interested members of the public.
Announcement -
PMPRB Hearing Panel issues decision in Procysbi case
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Procysbi, manufactured and marketed in Canada by Horizon Pharma.
Announcement